Leslie Scarlett, MD
Ophthalmology · N Charleston, SCNPI 1871676684
Payments from drug & device makers
Across 126 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$493
- AbbVie$301
- Novartis$279
- Oyster Point Pharma, Inc.$251
- Merz North America, Inc.$184
- Ocular Therapeutix, Inc.$180
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,99799%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 23 | $493 |
| AbbVie(2 entities) | 16 | $301 |
| Novartis | 8 | $279 |
| Oyster Point Pharma, Inc. | 11 | $251 |
| Merz North America, Inc. | 4 | $184 |
| Ocular Therapeutix, Inc. | 5 | $180 |
| Rayner Intraocular Lenses Limited | 3 | $163 |
| Tarsus Pharmaceuticals, Inc. | 6 | $136 |
| Thea Pharma Inc. | 4 | $134 |
| Glaukos Corporation | 5 | $128 |
| Sun Pharmaceutical Industries Inc. | 4 | $81 |
| Alcon Research LLC | 1 | $79 |
| Aerie Pharmaceuticals, Inc. | 5 | $78 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $57 |
| Bausch & Lomb Americas Inc. | 3 | $54 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $42 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| NEW World Medical,inc. | 3 | $38 |
| Amgen | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Staar Surgical Company | 1 | $27 |
| Dompe US, Inc. | 1 | $26 |
| Harrow Eye, LLC | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Biotissue Holdings Inc. | 1 | $16 |
| Akorn, Inc. | 1 | $14 |
| Omeros Corporation | 1 | $13 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
| Sight Sciences, Inc. | 1 | $12 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $12 |
| The North Carolina Mutual Wholesale Drug Company Inc | 2 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$124
How this compares
$3,016 in reported general payments places this provider in the 60th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 86 | $48,497 |
| RestasisCyclosporine | 23 | $31,942 |
| RhopressaNetarsudil Mesylate | 24 | $17,889 |
| XiidraLifitegrast | 14 | $12,426 |
| Alphagan PBrimonidine Tartrate | 19 | $8,496 |
| Latanoprost | 510 | $6,576 |
| Travoprost | 29 | $5,964 |
| Brimonidine Tartrate | 90 | $4,990 |
| Cyclosporine | 11 | $4,583 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 211 | $3,961 |
| Prednisolone Acetate | 60 | $3,633 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $3,285 |
| Pilocarpine Hcl | 32 | $2,490 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 16 | $2,363 |
| Ketorolac Tromethamine | 12 | $577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P | $301 | $88,935128 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $78 | $17,88924 claims |
| Bausch & Lomb Americas Inc.Xiidra | $54 | $12,42614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in N Charleston
- John WellsWest Columbia$7.1M
- William ClarkWest Columbia$6.2M
- Daniel AlfaroCharleston$4.6M
- Kerry SolomonMt Pleasant$4.6M
- Eric JablonCharleston$1.2M
- George WaringMt Pleasant$1M
- John KerrisonCharleston$975K
- Karolinne RochaCharleston$799K
- John PayneWest Columbia$574K
- Mona CamacciCharleston$534K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.